CLPT

ClearPoint Neuro Inc. (CLPT) | Rumor.io

ClearPoint Neuro

CLPT

Attention (50-day avg)0%

Attention rank (50-day avg)#881

Bullish sentiment (50-day avg)74%

Price to earnings ratio-17

Market capitalization467M

Earnings per share-1.18

Dividend yield (TTM)—

Revenue (annual)37M

Net income (annual)-25.5M

Social

What share of all stock conversation is about CLPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% 0	0% 0	0.01% 0

Sep 29

ClearPoint Neuro, Inc.'s ($CLPT) FDA approval for MCT8 deficiency treatment reflects the agency's commitment to patients with rare genetic diseases.
The company's revenue multiple and number of partners in clinical trials are being highlighted as positive indicators by some investors.
A gap down on similar volume has historically been followed by a series of green days in the stock, according to one observer.

Generated by AI

Sentiment

Of the messages about CLPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50%	93.51% +18.51	82.28% +21.61	92.67% +0.43
Bearish	50%	6.49% -18.51	17.72% -21.61	7.33% -0.43

Bullish· Jun 17

$CLPT's stock surged due to its role in delivering AMT-130 directly into the brain, a key factor in the FDA's accelerated approval of a BLA filing for Qure.
ClearPoint's partnership with Qure could lead to significant revenue increases, with each partner approval potentially resulting in a step-function increase, and 2-3 approvals potentially reaching $45-60.
The FDA's approval is a huge win for rare disease patients, and $CLPT's stock is still undervalued despite the recent surge, making it a promising investment opportunity.

Bearish· Jun 17

The short float on $CLPT was high at almost 18%, but the news did not have the expected impact.
The company's recent news and statements, including the CEO's optimistic comments, have not translated into significant price increases.
The asset is likely to drop, with some users predicting a return to $30 and others expecting a significant decline.

Generated by AI

Topics

Of the messages about CLPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	96.43%	86.84%	85.23%	86.14%
Technical Analysis	3.57%	13.16%	10.74%	4.91%
Earnings	0%	0%	3.69%	6.17%
Controversies	0%	0%	0.34%	1.29%
Analysts	0%	0%	0%	1.08%
Macro	0%	0%	0%	0.41%

Jun 17

ClearPoint Neuro's ($CLPT) stock surged 34% after the FDA allowed uniQure's ($QURE) three-year Phase I/II AMT-130 data to be used as the primary basis for an accelerated approval BLA filing.
The FDA's decision is a significant step forward for ClearPoint's precision MRI platform, which is used to deliver the one-time gene therapy AMT-130 directly into the brain.
ClearPoint's stock jumped 27% after uniQure's announcement, with the company's navigation platform and SmartFlow cannula system enabling precise intracerebral delivery of the gene therapy.

Generated by AI

Community

Of the messages about CLPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.14%	81.23%	84.49%	85.01%
Newcomers	2.86%	18.77%	15.51%	14.99%

Regulars· Sep 29

The FDA has approved ClearPoint Neuro, Inc.'s QURE treatment for MCT8 deficiency, a rare genetic disease, providing patients with a long-awaited treatment option.
The regulars are focused on the company's revenue multiple and its partnerships in clinical trials, which they believe will lead to the approval of QURE, despite current market skepticism.
The stock's price is influenced by market makers, and the regulars are skeptical of the current sentiment data, which they believe is not reflective of the company's true potential.

Newcomers· Jun 17

The FDA's decision to allow 3-year Phase I/II data from uniQure to support a BLA application for AMT-130 in Huntington’s disease has been seen as a positive development for ClearPoint Neuro, potentially leading to accelerated approval.
ClearPoint Neuro's navigation system is being used in the delivery of AMT-130, a therapy that could significantly increase the company's revenues, particularly if other partnerships are established in the next 2-3 years.
The FDA's loosening of policies on rare diseases could have a positive impact on ClearPoint Neuro's business, potentially leading to increased sales of consumable products from uniQure and a better financing environment, benefiting the company's partners.

Generated by AI

News

ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment

25d agoYahoo Finance

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Detailed price information for Clearpoint Neuro Inc (CLPT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about CLPT also mention

#	Name	Attention
1	uniQure N.V.QURE	0.02%+0.01
2	DMTK - DermTech, Inc.	——
3	MaxCyte, Inc.MXCT	0%0
4	Twist Bioscience CorporationTWST	0%-0.02
5	TransMedics Group, Inc.TMDX	0%-0.01
6	Harrow Inc.HROW	0%0
7	NeurAxis, Inc.NRXS	0%0
8	XPEL Inc.XPEL	0%0
9	KACL - Kairous Acquisition Corp. Limited	——
10	Pavmed Inc.PAVM	0%0

ClearPoint Neuro Inc.

Healthcare
Medical Devices

ClearPoint Neuro Inc. is a medical technology company focused on precision navigation and delivery solutions for complex neurological procedures. The company develops and commercializes platforms used in minimally invasive brain and spine interventions, combining hardware, disposable instruments, and software that support surgical planning, targeting, and procedure monitoring. Its product portfolio includes MRI-guided navigation systems, laser therapy tools, and therapy-delivery components designed to help clinicians access hard-to-reach areas of the central nervous system with greater control. ClearPoint Neuro also provides enabling services for cell, gene, and drug delivery programs, supporting medical and research partners with preclinical and clinical development workflows. The company serves healthcare and research centers across multiple global regions, making it an important specialist in image-guided neurosurgical technology and therapeutic delivery.

Website

Location

120 S. Sierra Avenue

Solana Beach, CA, 92075

United States

Social

What share of all stock conversation is about CLPT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0.01% 0	0% 0	0.01% 0

Sep 29

ClearPoint Neuro, Inc.'s ($CLPT) FDA approval for MCT8 deficiency treatment reflects the agency's commitment to patients with rare genetic diseases.
The company's revenue multiple and number of partners in clinical trials are being highlighted as positive indicators by some investors.
A gap down on similar volume has historically been followed by a series of green days in the stock, according to one observer.

Generated by AI

Sentiment

Of the messages about CLPT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50%	93.51% +18.51	82.28% +21.61	92.67% +0.43
Bearish	50%	6.49% -18.51	17.72% -21.61	7.33% -0.43

Bullish· Jun 17

$CLPT's stock surged due to its role in delivering AMT-130 directly into the brain, a key factor in the FDA's accelerated approval of a BLA filing for Qure.
ClearPoint's partnership with Qure could lead to significant revenue increases, with each partner approval potentially resulting in a step-function increase, and 2-3 approvals potentially reaching $45-60.
The FDA's approval is a huge win for rare disease patients, and $CLPT's stock is still undervalued despite the recent surge, making it a promising investment opportunity.

Bearish· Jun 17

The short float on $CLPT was high at almost 18%, but the news did not have the expected impact.
The company's recent news and statements, including the CEO's optimistic comments, have not translated into significant price increases.
The asset is likely to drop, with some users predicting a return to $30 and others expecting a significant decline.

Generated by AI

Topics

Of the messages about CLPT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	96.43%	86.84%	85.23%	86.14%
Technical Analysis	3.57%	13.16%	10.74%	4.91%
Earnings	0%	0%	3.69%	6.17%
Controversies	0%	0%	0.34%	1.29%
Analysts	0%	0%	0%	1.08%
Macro	0%	0%	0%	0.41%

Jun 17

ClearPoint Neuro's ($CLPT) stock surged 34% after the FDA allowed uniQure's ($QURE) three-year Phase I/II AMT-130 data to be used as the primary basis for an accelerated approval BLA filing.
The FDA's decision is a significant step forward for ClearPoint's precision MRI platform, which is used to deliver the one-time gene therapy AMT-130 directly into the brain.
ClearPoint's stock jumped 27% after uniQure's announcement, with the company's navigation platform and SmartFlow cannula system enabling precise intracerebral delivery of the gene therapy.

Generated by AI

Community

Of the messages about CLPT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	97.14%	81.23%	84.49%	85.01%
Newcomers	2.86%	18.77%	15.51%	14.99%

Regulars· Sep 29

The FDA has approved ClearPoint Neuro, Inc.'s QURE treatment for MCT8 deficiency, a rare genetic disease, providing patients with a long-awaited treatment option.
The regulars are focused on the company's revenue multiple and its partnerships in clinical trials, which they believe will lead to the approval of QURE, despite current market skepticism.
The stock's price is influenced by market makers, and the regulars are skeptical of the current sentiment data, which they believe is not reflective of the company's true potential.

Newcomers· Jun 17

The FDA's decision to allow 3-year Phase I/II data from uniQure to support a BLA application for AMT-130 in Huntington’s disease has been seen as a positive development for ClearPoint Neuro, potentially leading to accelerated approval.
ClearPoint Neuro's navigation system is being used in the delivery of AMT-130, a therapy that could significantly increase the company's revenues, particularly if other partnerships are established in the next 2-3 years.
The FDA's loosening of policies on rare diseases could have a positive impact on ClearPoint Neuro's business, potentially leading to increased sales of consumable products from uniQure and a better financing environment, benefiting the company's partners.

Generated by AI

ClearPoint Neuro

Social

Sep 29

Bullish· Jun 17

Bearish· Jun 17

Jun 17

Regulars· Sep 29

Newcomers· Jun 17

ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update

ClearPoint Neuro stock tumbles on uniQure trial setback

Stifel reiterates Clearpoint Neuro stock rating citing CGT focus

ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Also Discussed

ClearPoint Neuro Inc.

Company Information

Location

ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update

ClearPoint Neuro stock tumbles on uniQure trial setback

Stifel reiterates Clearpoint Neuro stock rating citing CGT focus

ClearPoint Neuro (CLPT) Stock Sees Fair Value Cut As Analysts Factor In Heavier Investment

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Sep 29

Bullish· Jun 17

Bearish· Jun 17

Jun 17

Regulars· Sep 29

Newcomers· Jun 17